Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Cystic Fibrosis Complicated by ABPA
NCT00787917Phase 4Terminated
- Sponsor
- Novartis
- Start
- Nov 2008
- Primary completion
- Jul 2010
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial in allergic bronchopulmonary aspergillosis (ABPA) comparing Omalizumab with Placebo (2 arms). Primary endpoint: Change From Baseline, as Measured by the Percentage of Participants Requiring Rescue With Corticosteroids, and as Measured by the Time to Deviation From the Protocol Prescribed Steroid Tapering… at 6 months. Started Nov 2008; status: terminated.
02
Drugs
omalizumab
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT00787917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787917.